OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026

As the 2026 ASCO Annual Meeting approaches, excitement is building across the lung cancer community for data that could redefine standards of care in both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). From long-term targeted therapy follow-up to emerging immunotherapy and cell therapy strategies, this year’s meeting in Chicago promises to spotlight advances across multiple disease settings.

To determine which abstracts have garnered the most interest, OncLive® conducted social media polls across LinkedIn and X.

Poll: What will your focus be in lung cancer at the 2026 ASCO Annual Meeting?

• Oncogene-driven NSCLC
• Adjuvant therapy in NSCLC
• 1L squamous NSCLC
• ES-SCLC

Among 30 respondents on LinkedIn, oncogene-driven NSCLC emerged as the leading area of interest heading into the meeting, receiving 60% of the vote. Adjuvant therapy in NSCLC, frontline squamous NSCLC, and extensive-stage SCLC (ES-SCLC) each garnered 13% of responses.

Conversely, among 6 respondents on X, oncogene-driven NSCLC emerged as the most anticipated focus area, receiving 50% of the vote. Frontline squamous NSCLC followed with 33% of responses, while ES-SCLC accounted for 17%. Adjuvant therapy in NSCLC did not receive any votes.

Poll: What lung cancer abstract(s) will have your attention at the 2026 ASCO Annual Meeting?

• LBA8500/8515/8502
• LBA3/8000
• LBA4
• LBA8005

When clinicians were asked to identify the single late-breaking abstract they were most looking forward to at ASCO, one LinkedIn respondent selected abstract(s) LBA3/8000, accounting for 100% of responses in that poll. On X, one respondent identified abstract LBA4 as the most anticipated presentation, also representing 100% of the vote.

Based on these results, OncLive pooled a list of the most closely followed lung cancer abstracts being presented at the 2026 ASCO Annual Meeting. Read on for more insights on each study.

Abstract LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28)

Presentation time: May 29, 1:00-1:12 PM CT

Location: Hall D2

Oncogene-driven disease will be highlighted by the phase 3 WU-KONG28 trial (NCT05668988), which compares sunvozertinib (Zegfrovy) with platinum-based chemotherapy in patients with locally advanced or metastatic EGFR exon 20 insertion–positive NSCLC. Non-classical EGFR mutations remain challenging to manage due to limited targeted treatment options and biologic heterogeneity. Investigators are especially interested in whether sunvozertinib can improve efficacy while opening the door for future combination approaches in this molecular subgroup.

Abstract 8515: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study

Presentation time: May 30, 1:45-1:51 PM CT

Location: Hall D2

Another closely watched study is the phase 2b TRITON trial (NCT06008093), evaluating tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and chemotherapy vs pembrolizumab (Keytruda) plus chemotherapy in metastatic nonsquamous NSCLC with STK11, KEAP1, and/or KRAS mutations. These molecular subsets have historically been associated with resistance to immunotherapy, making them a major unmet need in thoracic oncology. The interim analysis could help clarify whether dual checkpoint blockade strategies offer meaningful advantages in this difficult-to-treat population.

Abstract 8502: Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study

Presentation time: May 29, 2:00-2:12 PM CT

Location: Hall D2

One of the most anticipated presentations is the 7-year update from the phase 3 CROWN trial (NCT03052608) comparing lorlatinib (Lorbrena) with crizotinib (Xalkori) in frontline ALK-positive NSCLC. Earlier updates from the study demonstrated unprecedented progression-free survival and strong central nervous system protection, helping establish lorlatinib as a preferred first-line option for many patients. Investigators and clinicians alike are eager to see whether the durability of benefit continues at the 7-year mark and how the long-term safety profile evolves.

Abstract 8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST)

Presentation time: June 1, 1:15-1:27 PM CT

Location: Hall D1

Adjuvant immunotherapy will remain a major discussion point with results from the ECOG-ACRIN EA5142 ALCHEMIST study (NCT02595944). This randomized phase 3 trial is examining nivolumab (Opdivo) following surgery and adjuvant chemotherapy in patients with stage IB to IIIA NSCLC. The findings are particularly important, as many patients still undergo surgery before referral for neoadjuvant treatment, leaving room for effective postoperative strategies.

Abstract LBA3: Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion–positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial

Presentation time: May 31, 2:13-2:25 PM C

Location: Hall B1

The phase 3 LIBRETTO-432 trial (NCT04819100) will also command significant attention with its evaluation of adjuvant selpercatinib (Retevmo) in stage IB to IIIA RET fusion–positive NSCLC. Experts believe positive findings could establish a new standard of care for patients with resected RET-driven disease. The presentation also reflects the broader momentum toward bringing precision medicine into earlier-stage lung cancer settings to reduce recurrence risk and improve long-term survival.

Abstract LBA4: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial

Presentation time: May 31, 2:47-2:59 PM CT

Location: Hall B1

In advanced squamous NSCLC, the phase 3 HARMONi-6 study (NCT05840016) will present overall survival (OS) findings for ivonescimab plus chemotherapy vs tislelizumab-jsgr (Tevimbra) plus chemotherapy in the frontline setting. Clinicians are eager for new therapeutic strategies in squamous histology, where progress has often lagged behind nonsquamous disease. The results may provide insight into whether novel combination approaches can further improve outcomes for patients with metastatic squamous NSCLC.

Abstract LBA8005: Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial

Presentation time: June 1, 3:03-3:15 PM CT

Location: Hall D1

The phase 3 TRIPLEX trial (NCT05223647) is evaluating concurrent thoracic radiotherapy (TRT) combined with platinum/etoposide chemotherapy and durvalumab (Imfinzi) in patients with ES-SCLC. The trial explores whether adding TRT to the current immunotherapy-based standard of care can further improve outcomes such as OS and disease control in this aggressive cancer subtype. These findings may help define a new treatment strategy for ES-SCLC and could influence future clinical practice guidelines.

Want to learn more about why these abstracts are generating excitement? Check out this preview article featuring exclusive expert insights and visit our conference coverage page for daily updates on these presentations and more throughout the meeting.